ХРОНИЧЕСКИЕ ЗАБОЛЕВАНИЯ ПОЧЕК И НАРУШЕНИЯ СЕРДЕЧНОГО РИТМА
Аннотация
Представленный обзор посвящен актуальной проблеме современной кардионефрологии – нарушениям сердечного ритма при хронических заболеваниях почек. Обсуждаются различные аспекты фибрилляции предсердий, выявляемой у 16-21% больных с заболеваниями почек. Отдельно затрагиваются мероприятия по профилактике инсульта при этой аритмии, в частности эффективность, режимы дозировки и безопасность антикоагулянтной терапии, включая варфарин, апиксабан, дабигатран, эдоксабан и ривароксабан. Затронута роль антитромбоцитарных препаратов и окклюзии ушка левого предсердия в превентировании эмбологенных осложнений при хронических заболеваниях почек. Приведены сведения о восстановлении и контроле синусового ритма, а также контроле частоты сердечных сокращений при фибрилляции предсердий. Особое внимание уделено детальной характеристике различных антиаритмических препаратов, используемых для лечения различных видов нарушений ритма сердца, с учётом их связывания с белками крови, путей элиминации, диализируемости и наиболее частых побочных эффектов. Подчёркнута важность профилактики внезапной сердечной смерти у больных с хроническими заболеваниями почек, которые ответственны за 29-35% случаев всех причин смертности у этой категории больных.
Литература
1. Potpara T.S., Jokic V., Dagres N. et al. Cardiac arrhythmias in patients with chronic kidney disease: implications of renal failure for antiarrhythmic drug therapy. Curr Med Chem. 2016; 23 (19): 2070-2083.
2. Turakhia M.P, Blankestijn P.J., Carrero J.-J. et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018; 24: 2314-2325. doi: 10.1093/eurheartj/ehy060
3. Konstantinidis I., Nadkarni GN., Yacoub R. et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med 2016; 176: 121-124. doi: 10.1001/jamainternmed.2015.6102
4. Boriani G., Savelieva I., Dan GA. et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015; 17: 1169-1196. doi: 10.1093/europace/euv202
5. Priori S.G., Blomström-Lundqvist C., Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the. European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793-2867. doi: 10.1093/eurheartj/ehv316
6. Chugh S.S., Havmoeller R., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837-847. doi: 10.1161/CIRCULATIONAHA.113.005119
7. Eckardt K.U., Coresh J., Devuyst O. et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382: 158-169. doi: 10.1016/S0140-6736 (13)60439-0
8. Soliman E.Z., Prineas R.J., Go A.S. et al. Chronic Renal Insufficiency Cohort SG. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102-1107. doi: 10.1016/j.ahj.2010.03.027
9. Zimmerman D., Sood M.M., Rigatto C. et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27: 3816-3822. doi: 10.1093/ndt/gfs416
10. Shih C.J., Ou S.M., Chao P.W. et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation 2016; 133: 265-272. doi: 10.1161/CIRCULATIONAHA.115.018294
11. January C.T., Wann L.S., Alpert J.S. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21): e1-76. doi: 10.1016/j.jacc.2014.03.022
12. Kamel H., Okin P.M., Elkind M.S., Ladekola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016; 47; 895-900. doi: 10.1161/STROKEAHA.115.012004
13. Giugliano R.P., Ruff C.T., Braunwald E. et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22): 2093-2104. doi: 10.1056/NEJMoa1310907
14. Qamar A, Bhatt DL. Anticoagulation therapy: balancing the risks of stroke and bleeding in CKD. Nat Rev Nephrol 2015; 11 (4): 200-202. doi: 10.1038/nrneph.2015.14
15. Lau Y.C., Proietti M., Guiducci E. et al. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol. 2016; 68 (13): 1452-1464. doi: 10.1016/j.jacc.2016.06.057
16. Kirchhof P., Breithardt G., Bax J. et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace 2016; 18: 37-50. doi: 10.1093/europace/euv304
17. Bohm M., Ezekowitz M.D., Connolly S.J. et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 2015; 65: 2481-2493. doi: 10.1016/j.jacc.2015.03.577
18. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962. doi: 10.1093/eurheartj/ehw210
19. Doherty J.U., Gluckman T.J., Hucker W.J. et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 2017; 69: 871-898. doi: 10.1016/j.jacc.2016.11.024
20. Kai AM, Vadivelu N, Urman RD et al. Perioperative considerations in the management of anticoagulation therapy for patients undergoing surgery. Curr Pain Headache Rep. 2019; 23 (2): 13. doi: 10.1007/s11916-019-0747-3
21. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817. doi: 10.1056/NEJMoa1007432
22. Gibson C.M., Mehran R., Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423-2434. doi: 10.1056/NEJMoa1611594
23. Reddy V.Y., Doshi S.K., Kar S. et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017; 70 (24): 2964-2975. doi: 10.1016/j.jacc.2017.10.021
24. Weir M.A., Dixon S.N., Fleet J.L. et al. beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2015; 26: 987-996. doi: 10.1681/ASN.2014040324
25. Hoffmann K.J., Regardh C.G., Aurell M. et al. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet 1980; 5: 181-191.
26. Schmidt M., Daccarett M., Rittger H. et al. Renal dysfunction and atrial fibrillation recurrence following cardioversion. J Cardiovasc Electrophysiol 2011; 22: 1092-1098. doi: 10.1111/j.1540-8167.2011.02069.x
27. Li L., Wang Z.W., Li J. et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace 2014; 16: 1309-1314. doi: 10.1093/europace/euu066
28. Herzog C.A., Asinger R.W., Berger A.K. et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572-586. doi: 10.1038/ki.2011.223
29. Wong M.C., Kalman J.M., Pedagogos E. et al. Temporal distribution of arrhythmic events in chronic kidney disease: highest incidence in the long interdialytic period. Heart Rhythm 2015; 12: 2047-2055. doi: 10.1016/j.hrthm.2015.06.033
30. Nakhoul G.N., Schold J.D., Arrigain S. et al. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis. Clin J Am Soc Nephrol 2015; 10: 1119-1127. doi: 10.2215/CJN.11121114
2. Turakhia M.P, Blankestijn P.J., Carrero J.-J. et al. Chronic kidney disease and arrhythmias: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Eur Heart J. 2018; 24: 2314-2325. doi: 10.1093/eurheartj/ehy060
3. Konstantinidis I., Nadkarni GN., Yacoub R. et al. Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review. JAMA Intern Med 2016; 176: 121-124. doi: 10.1001/jamainternmed.2015.6102
4. Boriani G., Savelieva I., Dan GA. et al. Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices: clinical significance and implications for decision making-a position paper of the European Heart Rhythm Association endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Europace 2015; 17: 1169-1196. doi: 10.1093/europace/euv202
5. Priori S.G., Blomström-Lundqvist C., Mazzanti A. et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the. European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36: 2793-2867. doi: 10.1093/eurheartj/ehv316
6. Chugh S.S., Havmoeller R., Narayanan K. et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837-847. doi: 10.1161/CIRCULATIONAHA.113.005119
7. Eckardt K.U., Coresh J., Devuyst O. et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382: 158-169. doi: 10.1016/S0140-6736 (13)60439-0
8. Soliman E.Z., Prineas R.J., Go A.S. et al. Chronic Renal Insufficiency Cohort SG. Chronic kidney disease and prevalent atrial fibrillation: the Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102-1107. doi: 10.1016/j.ahj.2010.03.027
9. Zimmerman D., Sood M.M., Rigatto C. et al. Systematic review and meta-analysis of incidence, prevalence and outcomes of atrial fibrillation in patients on dialysis. Nephrol Dial Transplant 2012; 27: 3816-3822. doi: 10.1093/ndt/gfs416
10. Shih C.J., Ou S.M., Chao P.W. et al. Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation 2016; 133: 265-272. doi: 10.1161/CIRCULATIONAHA.115.018294
11. January C.T., Wann L.S., Alpert J.S. American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64 (21): e1-76. doi: 10.1016/j.jacc.2014.03.022
12. Kamel H., Okin P.M., Elkind M.S., Ladekola C. Atrial fibrillation and mechanisms of stroke: time for a new model. Stroke. 2016; 47; 895-900. doi: 10.1161/STROKEAHA.115.012004
13. Giugliano R.P., Ruff C.T., Braunwald E. et al. ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22): 2093-2104. doi: 10.1056/NEJMoa1310907
14. Qamar A, Bhatt DL. Anticoagulation therapy: balancing the risks of stroke and bleeding in CKD. Nat Rev Nephrol 2015; 11 (4): 200-202. doi: 10.1038/nrneph.2015.14
15. Lau Y.C., Proietti M., Guiducci E. et al. Atrial fibrillation and thromboembolism in patients with chronic kidney disease. J Am Coll Cardiol. 2016; 68 (13): 1452-1464. doi: 10.1016/j.jacc.2016.06.057
16. Kirchhof P., Breithardt G., Bax J. et al. A roadmap to improve the quality of atrial fibrillation management: proceedings from the fifth Atrial Fibrillation Network/European Heart Rhythm Association consensus conference. Europace 2016; 18: 37-50. doi: 10.1093/europace/euv304
17. Bohm M., Ezekowitz M.D., Connolly S.J. et al. Changes in renal function in patients with atrial fibrillation: an analysis from the RE-LY trial. J Am Coll Cardiol 2015; 65: 2481-2493. doi: 10.1016/j.jacc.2015.03.577
18. Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016; 37: 2893-2962. doi: 10.1093/eurheartj/ehw210
19. Doherty J.U., Gluckman T.J., Hucker W.J. et al. 2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a Report of the American College of Cardiology Clinical Expert Consensus Document Task Force. J Am Coll Cardiol 2017; 69: 871-898. doi: 10.1016/j.jacc.2016.11.024
20. Kai AM, Vadivelu N, Urman RD et al. Perioperative considerations in the management of anticoagulation therapy for patients undergoing surgery. Curr Pain Headache Rep. 2019; 23 (2): 13. doi: 10.1007/s11916-019-0747-3
21. Connolly S.J., Eikelboom J., Joyner C. et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011; 364: 806-817. doi: 10.1056/NEJMoa1007432
22. Gibson C.M., Mehran R., Bode C. et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med 2016; 375: 2423-2434. doi: 10.1056/NEJMoa1611594
23. Reddy V.Y., Doshi S.K., Kar S. et al. 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol 2017; 70 (24): 2964-2975. doi: 10.1016/j.jacc.2017.10.021
24. Weir M.A., Dixon S.N., Fleet J.L. et al. beta-Blocker dialyzability and mortality in older patients receiving hemodialysis. J Am Soc Nephrol 2015; 26: 987-996. doi: 10.1681/ASN.2014040324
25. Hoffmann K.J., Regardh C.G., Aurell M. et al. The effect of impaired renal function on the plasma concentration and urinary excretion of metoprolol metabolites. Clin Pharmacokinet 1980; 5: 181-191.
26. Schmidt M., Daccarett M., Rittger H. et al. Renal dysfunction and atrial fibrillation recurrence following cardioversion. J Cardiovasc Electrophysiol 2011; 22: 1092-1098. doi: 10.1111/j.1540-8167.2011.02069.x
27. Li L., Wang Z.W., Li J. et al. Efficacy of catheter ablation of atrial fibrillation in patients with obstructive sleep apnoea with and without continuous positive airway pressure treatment: a meta-analysis of observational studies. Europace 2014; 16: 1309-1314. doi: 10.1093/europace/euu066
28. Herzog C.A., Asinger R.W., Berger A.K. et al. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: improving Global Outcomes (KDIGO). Kidney Int 2011; 80: 572-586. doi: 10.1038/ki.2011.223
29. Wong M.C., Kalman J.M., Pedagogos E. et al. Temporal distribution of arrhythmic events in chronic kidney disease: highest incidence in the long interdialytic period. Heart Rhythm 2015; 12: 2047-2055. doi: 10.1016/j.hrthm.2015.06.033
30. Nakhoul G.N., Schold J.D., Arrigain S. et al. Implantable cardioverter-defibrillators in patients with CKD: a propensity-matched mortality analysis. Clin J Am Soc Nephrol 2015; 10: 1119-1127. doi: 10.2215/CJN.11121114
Опубликована
2019-10-01
Как цитировать
ВАТУТИН, Н. Т. et al.
ХРОНИЧЕСКИЕ ЗАБОЛЕВАНИЯ ПОЧЕК И НАРУШЕНИЯ СЕРДЕЧНОГО РИТМА.
Университетская клиника, [S.l.], n. 3(32), p. 65-70, окт. 2019.
ISSN 1819-0464. Доступно на: <http://journal.dnmu.ru/index.php/UC/article/view/341>. Дата доступа: 25 апр. 2024
doi: https://doi.org/10.26435/uc.v0i3(32).341.
Раздел
Обзоры
